Flottmann, F.
van Horn, N. http://orcid.org/0000-0001-5764-1982
Maros, M. E.
Leischner, H.
Bechstein, M.
Meyer, L.
Sauer, M.
Deb-Chatterji, M.
Alegiani, A.
Thomalla, G.
Fiehler, J.
Brekenfeld, C.
,
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 17 March 2021
Accepted: 10 June 2021
First Online: 8 July 2021
Conflict of interest
: N. van Horn, H. Leischner, M. Bechstein, L. Meyer, M. Sauer, M. Deb-Chatterji, A. Alegiani and C. Brekenfeld declare that they have no competing interests. J. Fiehler reports unrelated consultancy for Acandis, Boehringer Ingelheim, Cerenovus, Covidien, Evasc Neurovascular, MD-Clinicals, Medtronic, Medina, MicroVention, Penumbra, Route 92 Medical, Stryker, Transverse Medical. Grants/grants pending: MicroVention, Medtronic, Stryker, Cerenovus. CEO Eppdata. F. Flottmann reports unrelated personal fees from Eppdata GmbH outside the submitted work. M.E. Maros reports funding from the German Federal Ministry for Economic Affairs and Energy within the scope of <i>Zentrales Innovationsprogramm Mittelstand</i> (ZF 4514602TS8) outside the submitted work and unrelated consultancy for Siemens Healthineers. G. Thomalla reports unrelated consultancy for Acandis, Stryker; payment for lectures including service on speakers bureaus: Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo; personal fees from Portola and Biogen outside the submitted work.